1st September 2024
Barzolvolimab shows profound efficacy and favorable safety over 52 weeks in patients with Chronic Spontaneous Urticaria
1st February 2024
Barzolvolimab Significantly Decreases Chronic Spontaneous Urticaria Disease Activity and is Well Tolerated: Top Line Results from a Phase 2 Trial
1st November 2023
Barzolvolimab Demonstrates Safety and Clinically Meaningful Activity in Moderate-Severe Prurigo Nodularis
1st October 2023
Patients With Chronic Spontaneous Urticaria Experience Improvement in Quality of Life When Treated With Barzolvolimab
1st June 2023
Barzolvolimab Demonstrates Clinical Activity in a Multiple Ascending Dose Trial in Chronic Spontaneous Urticaria
1st February 2023
Safety and Clinical Activity of Multiple Doses of Barzolvolimab, an anti-KIT Antibody, in Patients with Chronic Spontaneous Urticaria
1st December 2022